Celldex Therapeutics’ (CLDX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a research report sent to investors on Thursday, Benzinga reports. They currently have a $80.00 price target on the biopharmaceutical company’s stock.

A number of other equities research analysts have also commented on the company. Wells Fargo & Company upped their target price on Celldex Therapeutics from $35.00 to $37.00 and gave the company an equal weight rating in a research report on Monday, August 12th. Stifel Nicolaus assumed coverage on shares of Celldex Therapeutics in a report on Tuesday, June 18th. They issued a buy rating and a $58.00 price objective on the stock. Cantor Fitzgerald reissued an overweight rating and set a $67.00 target price on shares of Celldex Therapeutics in a report on Monday, September 16th. Finally, Wolfe Research reaffirmed an outperform rating and issued a $51.00 price target on shares of Celldex Therapeutics in a report on Wednesday, September 25th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of Buy and a consensus target price of $63.83.

Celldex Therapeutics Trading Up 1.0 %

NASDAQ CLDX opened at $33.20 on Thursday. Celldex Therapeutics has a 12-month low of $22.11 and a 12-month high of $53.18. The company has a fifty day simple moving average of $38.35 and a two-hundred day simple moving average of $38.29. The stock has a market cap of $2.19 billion, a P/E ratio of -11.65 and a beta of 1.56.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.05. The company had revenue of $2.50 million during the quarter, compared to analyst estimates of $1.13 million. Celldex Therapeutics had a negative return on equity of 23.66% and a negative net margin of 1,809.18%. As a group, sell-side analysts forecast that Celldex Therapeutics will post -2.5 earnings per share for the current year.

Institutional Investors Weigh In On Celldex Therapeutics

Institutional investors have recently modified their holdings of the business. Point72 Asia Singapore Pte. Ltd. acquired a new position in Celldex Therapeutics in the 2nd quarter worth about $76,000. Teachers Retirement System of The State of Kentucky increased its position in shares of Celldex Therapeutics by 32.0% in the second quarter. Teachers Retirement System of The State of Kentucky now owns 40,558 shares of the biopharmaceutical company’s stock valued at $1,501,000 after buying an additional 9,829 shares in the last quarter. Novo Holdings A S acquired a new position in shares of Celldex Therapeutics during the 2nd quarter worth approximately $31,458,000. Algert Global LLC lifted its position in shares of Celldex Therapeutics by 75.6% during the 2nd quarter. Algert Global LLC now owns 75,614 shares of the biopharmaceutical company’s stock valued at $2,798,000 after buying an additional 32,564 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. grew its stake in Celldex Therapeutics by 47.5% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 845,560 shares of the biopharmaceutical company’s stock valued at $31,294,000 after acquiring an additional 272,389 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.